<DOC>
	<DOCNO>NCT01974440</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety PCI-32765 ( ibrutinib ) administer combination either bendamustine rituximab ( BR ) rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone ( R-CHOP ) adult participant previously treat indolent Non-Hodgkin lymphoma .</brief_summary>
	<brief_title>A Study PCI-32765 ( Ibrutinib ) Combination With Either Bendamustine Rituximab Rituximab , Cyclophosphamide , Doxorubicin , Vincristine , Prednisone Participants With Previously Treated Indolent Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>This randomize ( individual assign study treatment chance ) , double-blind ( individual study personnel know identity study treatment ) , placebo ( inactive substance compare drug test whether drug real effect clinical trial ) -controlled study approximately 400 adult participant follicular lymphoma marginal zone lymphoma . The study include follow phase : Screening , Treatment , Post-treatment Follow-up . Eligible participant randomly assign 1:1 ratio either treatment Arm A ( background immune-chemotherapy + placebo ) treatment Arm B ( background immune-chemotherapy + 560 milligram [ mg ] ibrutinib ) . All participant receive 6 cycle background immune-chemotherapy either BR R-CHOP combination either placebo ( Arm A ) ibrutinib ( Arm B ) . Selection background immune-chemotherapy base prior treatment history cardiac function . After completion background immune-chemotherapy , study drug ( ibrutinib placebo ) continue disease progression , unacceptable toxicity , study end , whichever come first . Assessment tumor response progression conduct accordance Revised Response Criteria Malignant Lymphoma . Serial pharmacokinetic ( study drug body ) blood sample collect . Safety assess throughout study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically confirm diagnosis Bcell indolent NonHodgkin lymphoma histological subtype limit follicular lymphoma marginal zone lymphoma , initial diagnosis without evidence pathological transformation clinical sign suggest transformation At least 1 prior treatment CD20 antibody combination chemoimmunotherapy regimen Disease relapse refractory prior chemoimmunotherapy At least 1 measurable site disease accord Revised Response Criteria Malignant Lymphoma 2007 Eastern Cooperative Oncology Group performance status grade 0 1 Laboratory value within protocoldefined parameter Agrees protocoldefined use effective contraception Men must agree donate sperm study 6 month last dose bendamustine , 12 month last dose rituximab , 3 month last dose study medication , whichever later Women childbearing potential must negative serum urine pregnancy test Screening Prior treatment accord protocoldefined criterion Unable receive background chemotherapy base prior treatment history cardiac function Known central nervous system lymphoma Diagnosed treated malignancy indolent NonHodgkin lymphoma History stroke intracranial hemorrhage within 6 month prior randomization Requires anticoagulation warfarin equivalent Vitamin K antagonists Requires treatment strong CYP3A inhibitor Clinically significant cardiovascular disease Known history human immunodeficiency virus active hepatitis C virus ( HCV ; ribonucleic acid [ RNA ] polymerase chain reaction [ PCR ] positive ) active hepatitis B virus ( HBV ; DNA PCRpositive ) infection uncontrolled active systemic infection require intravenous antibiotic Any lifethreatening illness , medical condition , organ system dysfunction , Investigator 's opinion , could compromise participant 's safety , interfere absorption metabolism ibrutinib capsule , put study outcome undue risk Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Follicular lymphoma</keyword>
	<keyword>Marginal zone lymphoma</keyword>
	<keyword>Indolent Non-Hodgkin lymphoma</keyword>
	<keyword>PCI-32765</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Prednisone</keyword>
	<keyword>R-CHOP</keyword>
</DOC>